Cytokinetics schedules 2026 Annual Meeting May 27 with CEO performance overview.

Cytokinetics, a cardiovascular biopharmaceutical company, announced its 2026 Annual Meeting of Stockholders will be held on May 27 at its South San Francisco headquarters. CEO Robert I. Blum will present an overview of the company's performance immediately after the meeting. Stockholders of record as of March 31, 2026, can vote in person or by proxy by May 26. The company is advancing cardiac muscle disease treatments, including the approved MYQORZO® for obstructive hypertrophic cardiomyopathy and ongoing trials for other heart failure therapies.